ALAMEDA, Calif., Oct. 27 /PRNewswire/ -- Avigen (Nasdaq: AVGN) scientists and their collaborators in Japan announced the successful application of their adeno-associated virus (AAV) vector approach to gene therapy for use in the treatment of Parkinson's disease in an animal model of that illness. ...